| (Values in U.S. Thousands) | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 |
| Sales | 24,780 | 22,590 | 21,200 | 20,490 | 18,530 |
| Sales Growth | +9.69% | +6.56% | +3.47% | +10.58% | +7.73% |
| Net Income | -13,530 | -13,470 | -13,640 | -12,780 | -12,580 |
| Net Income Growth | -0.45% | +1.25% | -6.73% | -1.59% | -20.73% |
Ceribell Inc (CBLL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
CeriBell Inc. is a commercial-stage medical technology company. It focused on transforming the diagnosis and management of patients with serious neurological conditions. The company is an AI-powered, rapidly deployable point-of-care electroencephalography platform designed to address the unmet needs of patients in the acute care setting. CeriBell Inc. is based in Sunnyvale, Calif.
Fiscal Year End Date: 12/31